menu
    • menu
    [{"orgOrder":0,"company":"Expert Systems","sponsor":"Lomond Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Lonitoclax","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Expert Systems","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Expert Systems \/ Lomond Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Expert Systems \/ Lomond Therapeutics"},{"orgOrder":0,"company":"Lomond Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Lonitoclax","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Lomond Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lomond Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Lomond Therapeutics \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Lonitoclax

    Menu

    Lonitoclax

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Expert Systems

                            U.S.A arrow
                            Vitafoods
                            Not Confirmed

                            Expert Systems

                            U.S.A arrow
                            Vitafoods
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lonitoclax

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Lomond Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Expert Systems Celebrates Milestone in Clinical Development of Lonitoclax BCL-2 Inhibitor

                            Details : Lonitoclax has a best-in-class potency and selectivity against BCL-2. Currently, it is being evaluated for the treatment of chronic lymphocytic leukemia.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            December 17, 2024

                            Lead Product(s) : Lonitoclax

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Lomond Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Lomond Therapeutics

                            U.S.A arrow
                            Vitafoods
                            Not Confirmed

                            Lomond Therapeutics

                            U.S.A arrow
                            Vitafoods
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lonitoclax

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Lomond’s Lonitoclax IND Cleared by FDA for Chronic Lymphocytic Leukemia

                            Details : Lonitoclax has a best-in-class potency and selectivity against BCL-2. Currently, it is being evaluated for the treatment of chronic lymphocytic leukemia.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            October 15, 2024

                            Lead Product(s) : Lonitoclax

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth